Early treatment favored in AMA journal

October 2006
Inside MS;Oct/Nov2006, Vol. 24 Issue 5, p33
Academic Journal
The article highlights the issues discussed on two articles about the treatment of multiple sclerosis (MS), published in the April 2006 issue of the Archives of Neurology. In his article, Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should Be Treated at the Time of Diagnosis, Elliot Frohman and colleagues emphasized their views on MS treatment. While Sean J. Pittock argued that not all patients with MS should be treated at the time of diagnosis.


Related Articles

  • Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patient with multiple sclerosis treated with interferon β-1 a: analysis of the PRISMS study. Freedman, M. S.; Forrestal, F. G. // Multiple Sclerosis (13524585);Nov2008, Vol. 14 Issue 9, p1234 

    Background Early intervention with an effective disease-modifying drug (DMD) offers the best chance of limiting the inflammatory process that contributes to irreversible axonal damage correlating with disability in multiple sclerosis (MS). It is equally important to ascertain fairly quickly...

  • Multiple sclerosis update. Jones, Christine // Primary Health Care;Mar2004, Vol. 14 Issue 2, p26 

    Presents variety of effective management strategies for Multiple sclerosis (MS). Etiology of MS; Prevalence, incidence and epidemiology of the condition; Common symptoms; Diagnosis and prognosis; Management strategies.

  • One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis. Z�phir, H.; de Seze, J.; Dujardin, K.; Dubois, G.; Cabaret, M.; Bouillaguet, S.; Ferriby, D.; Stojkovic, T.; Vermersch, P. // Multiple Sclerosis (13524585);Jun2005, Vol. 11 Issue 3, p360 

    We conducted an evaluation of changes in cognition in progressive multiple sclerosis (MS) patients receiving monthly intravenously pulse of cyclophosphamide (700 mg/m2) with methylprednisolone (1 g). Twenty-eight consecutive progressive MS patients (10 primary progressive, 18 secondary...

  • Factors related with treatment adherence to interferon � and glatiramer acetate therapy in multiple sclerosis. R�o, Jordi; Porcel, Joana; T�llez, Nieves; S�nchez-Betancourt, Angela; Tintor�, Mar; Ar�valo, M. Jes�s; Nos, Carlos; Montalban, Xavier // Multiple Sclerosis (13524585);Jun2005, Vol. 11 Issue 3, p306 

    Background: Awareness of the factors influencing discontinuation of immunomodulatory drugs (IMD) treatment in multiple sclerosis (MS) can help to find approaches to patient management with the aim of establishing more specific indications and also attaining more optimal patient selection in...

  • Oral treatment reduces multiple sclerosis flare-ups. Stein, Jill // Drug Topics;6/16/2008, Vol. 152 Issue 7, Special section p4 

    The article discusses the effect of oral treatment on patients with multiple sclerosis. According to a report, patients receiving investigational oral immunomodulator fingolimod remained relapse-free after three years of treatment. It describes the results of an extension study in 173 patients...

  • an Overview of MS. Guarnaccia, Joseph B.; Booss, John // PN;Feb2005, Vol. 59 Issue 2, p32 

    Presents facts and information about multiple sclerosis. Clinical definition; People that are afflicted by multiple sclerosis and its genetic factors; Diagnosis and symptoms; Prospects for multiple sclerosis treatments. INSET: NEW EDITION OF MS WELLNESS GUIDE.

  • Azathioprine myelosuppression in multiple sclerosis: characterizing thiopurine methyltransferase polymorphisms. Frohman, E. M.; Havrdova, E.; Levinson, B.; Slanar, O. // Multiple Sclerosis (13524585);Feb2006, Vol. 12 Issue 1, p108 

    We describe two multiple sclerosis patients who developed pancytopenia following treatment with azathioprine. They were found to have the homozygous polymorphism for thiopurine methyltransferase deficiency and recovered after cessation of drug therapy. We review the literature concerning this...

  • Disease-modifying therapies and symptomatic treatments for MS patients. Boothby, Lisa; Doering, Paul L. // Drug Topics;10/25/2004, Vol. 148 Issue 20, p37 

    This article aims to review the pharmacology, efficacy, and safety profiles for the common disease-modifying therapies used to control symptoms often encountered in multiple sclerosis patients. It presents an outline of what is known about the pathophysiology of multiple sclerosis (MS). It...

  • The Lesions of Multiple Sclerosis. Paty, Donald W.; Arnold, Douglas L. // New England Journal of Medicine;1/17/2002, Vol. 346 Issue 3, p199 

    Editorial. Discusses multiple sclerosis (MS). Reference to reports by Chang and colleagues and by Brex et al in this issue; How the findings are important to an understanding of the remyelination of lesions of MS and imply that transplantation of oligodendrocyte precursor cells will probably not...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics